A) Selection Original papers

1. Wrona D, Siler U*, Reichenbach J*. Novel Diagnostic Tool for p47phox-Deficient Chronic Granulomatous Disease Patient and Carrier Detection. Mol Ther Methods Clin Dev 2019;13: 274–278.  * Equal contribution
2. Wrona D, Siler U*, Reichenbach J*. CrispR/Cas9-generated p47phox-deficient cell line for Chronic Granulomatous Disease gene therapy vector development. Scientific Reports (Nature Publishing Group) 2017;7:44187 * Equal contribution
3. Weisser M, Demel UM, Stein S, Chen-Wichmann L, Touzot F, Santilli G, Sujer S, Brendel C, Siler U, Cavazzana M, Thrasher AJ, Reichenbach J, Essers MA, Schwäble J, Grez M. Hyperinflammation in Chronic Granulomatous Disease leads to impairment of hematopoietic stem cell functions. J Allergy Clin Immunol 2016, 138(1):219-228.e9.
4. Romao S, Tejera Puente E, Nytko KJ, Siler U, Münz C, Reichenbach J. Defective nuclear entry of hydrolases prevents NETosis in Chronic Granulomatous Disease. J Allergy Clin Immunol 2015; 136(6):1703-1706.e5
5. Dreyer AK, Hoffmann D, Lachmann N, Ackermann M, Steinemann D, Timm B, Siler U, Reichenbach J, Grez M, Moritz T, Schambach A, Cathomen T. TALEN-mediated functional correction of X-linked chronic Granulomatous disease in patient-derived induced pluripotent stem cells. Biomaterials 2015; 69:191-200.
6. Galy A, Thrasher A, Grez, M, Schwaeble J, Reichenbach J,  Cavazzana M, Pouillot S, Kuehlcke K, Schmidt M, Paprotka T, Schreiber A, Koubi D. Gene Therapy for X-Linked Chronic Granulomatous Disease (Net4CGD). Hum Gene Ther Clin Methods 2015;26(2):88-90
7. Siler U*, Paruzynski A*, Holtgreve-Grez H, Kuzmenko E, Koehl U, Renner ED, Alhan C, van de Loosdrecht AA, Schwäble J, Pfluger T, Tchinda J, Schmugge M, Jauch A, Naundorf S, Kühlcke K, Notheis G, Güngör T, v. Kalle C, Schmidt M* Equal contribution, Grez M*, Seger R*, Reichenbach J*. Sequential gene therapy and successful rescue HSCT in two children with X-CGD – importance of timing. Curr Gene Ther 2015;15(4):416-27 * Equal contribution

B) Reviews and Book chapters

1. Kaufmann K, Chiriaco M, Siler U, Finocchi A, Reichenbach J, Stein S, Grez M. Gene Therapy for Chronic Granulomatous Disease: Current Status and Future Perspectives. Current Gene Therapy 2014; 14(6) : 447-460
2. Kaufmann K, Chiriaco M, Siler U, Finocchi A, Reichenbach J, Stein S, Grez M. Gene Therapy for Chronic Granulomatous Disease: Current Status and Future Perspectives. Current Gene Therapy 2014; 14(6) : 447-460

A) Selection Original Papers

1. Jínek M. Uncut but Primed for Change. CRISPR J. 2019 Dec;2(6):352-354.
2. Dumeau CE, Monfort A, Kissling L, Swarts DC, Jinek M, Wutz A. Introducing gene deletions by mouse zygote electroporation of Cas12a/Cpf1. Transgenic Res. 2019 Dec;28(5-6):525-535.
3. Ricci CG, Chen JS, Miao Y, Jinek M, Doudna JA, McCammon JA, Palermo G. Deciphering Off-Target Effects in CRISPR-Cas9 through Accelerated Molecular Dynamics. ACS Cent Sci. 2019 Apr 24;5(4):651-662.
4. Kissling L, Monfort A, Swarts DC, Wutz A, Jinek M. Preparation and electroporation of Cas12a/Cpf1-guide RNA complexes for introducing large gene deletions in mouse embryonic stem cells. Methods Enzymol. 2019;616:241-263.
5. Savić N, Ringnalda FC, Berk C, Bargsten K, Hall J, Jinek M, Schwank G. In vitro Generation of CRISPR-Cas9 Complexes with Covalently Bound Repair Templates  for Genome Editing in Mammalian Cells. Bio Protoc. 2019 Jan 5;9(1).
6. Swarts DC, Jinek M. Mechanistic Insights into the cis- and trans-Acting DNase Activities of Cas12a. Mol Cell. 2019 Feb 7;73(3):589-600.e4.